Study of ponsegromab for lung cancer weight loss
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a medicine called ponsegromab for people with advanced lung cancer who have lost significant weight (cachexia). If you qualify, you'll receive ponsegromab along with your first dose of durvalumab immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that cannot be surgically removed.
- You've completed chemotherapy with radiation 7 to 42 days ago and your cancer hasn't worsened.
- You are about to start durvalumab (immunotherapy) for up to 12 months.
- You have lost weight without trying: either more than 2% if your BMI is under 20, or more than 5% in the last 6 months.
- No other cause for weight loss (like severe COPD) and no heart failure.
- No brain symptoms from cancer spread, and you haven't had another cancer in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
This trial tests a new appetite-boosting medicine (nano-crystalline megestrol acetate) added to standard chemotherapy for people with advanced small cell lung cancer who are losing weight. It aims to see if it helps with weight, strength, and treatment response.
This study tests whether a drug called selpercatinib can help patients with advanced lung, pancreatic, or colorectal cancer who are losing weight while on chemotherapy. It aims to see if the drug is safe and might reverse or prevent further weight loss.
This trial tests a combination of nanocrystalline megestrol (a medicine to improve appetite and weight) with standard chemotherapy and immunotherapy as a first treatment for people with extensive-stage small cell lung cancer who have lost weight or have early signs of cachexia (wasting syndrome). The goal is to see if this approach can help you feel better and live longer.
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
This trial tests whether a postbiotic supplement can help people with advanced non-small-cell lung cancer who are losing weight (cachexia). If you're getting or have finished chemotherapy plus immunotherapy for stage III or IV NSCLC and have lost weight recently, you may be able to join.
Hear when a new Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.